EP4050997A4 - Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline - Google Patents

Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline Download PDF

Info

Publication number
EP4050997A4
EP4050997A4 EP20881057.2A EP20881057A EP4050997A4 EP 4050997 A4 EP4050997 A4 EP 4050997A4 EP 20881057 A EP20881057 A EP 20881057A EP 4050997 A4 EP4050997 A4 EP 4050997A4
Authority
EP
European Patent Office
Prior art keywords
treatment
receptor antagonists
endothelin receptor
ocular diseases
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20881057.2A
Other languages
German (de)
English (en)
Other versions
EP4050997A1 (fr
Inventor
Sevgi GURKAN
David Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perfuse Therapeutics Inc
Original Assignee
Perfuse Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc filed Critical Perfuse Therapeutics Inc
Priority to EP22176530.8A priority Critical patent/EP4094759A1/fr
Publication of EP4050997A1 publication Critical patent/EP4050997A1/fr
Publication of EP4050997A4 publication Critical patent/EP4050997A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20881057.2A 2019-10-30 2020-10-30 Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline Pending EP4050997A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22176530.8A EP4094759A1 (fr) 2019-10-30 2020-10-30 Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928092P 2019-10-30 2019-10-30
US202063068215P 2020-08-20 2020-08-20
PCT/US2020/058411 WO2021087399A1 (fr) 2019-10-30 2020-10-30 Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP22176530.8A Division-Into EP4094759A1 (fr) 2019-10-30 2020-10-30 Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline
EP22176530.8A Division EP4094759A1 (fr) 2019-10-30 2020-10-30 Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline

Publications (2)

Publication Number Publication Date
EP4050997A1 EP4050997A1 (fr) 2022-09-07
EP4050997A4 true EP4050997A4 (fr) 2022-11-30

Family

ID=75715356

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20881057.2A Pending EP4050997A4 (fr) 2019-10-30 2020-10-30 Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline
EP22176530.8A Pending EP4094759A1 (fr) 2019-10-30 2020-10-30 Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22176530.8A Pending EP4094759A1 (fr) 2019-10-30 2020-10-30 Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline

Country Status (9)

Country Link
US (3) US20220257505A1 (fr)
EP (2) EP4050997A4 (fr)
JP (1) JP2022554277A (fr)
CN (2) CN118203574A (fr)
AU (1) AU2020373065A1 (fr)
CA (1) CA3158767A1 (fr)
IL (1) IL292350A (fr)
MX (1) MX2022005063A (fr)
WO (1) WO2021087399A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005063A (es) 2019-10-30 2022-08-04 Perfuse Therapeutics Inc Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
IL294873A (en) 2020-02-06 2022-09-01 Perfuse Therapeutics Inc Preparations for the treatment of eye diseases
IL307997A (en) 2021-04-30 2023-12-01 Perfuse Therapeutics Inc Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
WO2016156639A1 (fr) * 2015-03-27 2016-10-06 Retinset, S.L. Formulation ophtalmique topique d'antagonistes du récepteur de l'endothéline
WO2021158663A1 (fr) * 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions pour le traitement de maladies oculaires

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020784A1 (fr) * 1992-04-10 1993-10-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Micro-aiguille d'injection destinee a des vaisseaux sanguins oculaires
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
CZ20032350A3 (en) * 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070260203A1 (en) 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
EP2190433A2 (fr) 2007-08-22 2010-06-02 Gilead Colorado, Inc. Thérapie pour complications du diabète
US8980874B2 (en) 2009-04-30 2015-03-17 Midwestern University Method and composition for treating diabetic ketoacidosis
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
EP2558104A4 (fr) 2010-04-12 2013-12-11 R Tech Ueno Ltd Procédé et composition ophtalmique pour traiter une maladie rétinienne
KR101898358B1 (ko) * 2013-12-19 2018-09-12 타소스 지오지우 신경계 손상을 수반하는 질병을 치료하기 위한 오메가 3 지방산 조성물
EP3302469A1 (fr) * 2015-05-29 2018-04-11 Edge Therapeutics, Inc. Compositions et méthodes pour diminuer une perte de la vision
WO2017217967A1 (fr) * 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Nouveaux procédés d'administration d'agents thérapeutiques à l'œil par l'intermédiaire des voies nasales
WO2018185516A1 (fr) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques destinées à traiter une toxicité cardiovasculaire induite par une thérapie anticancéreuse
SG11201912267SA (en) * 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
CA3070241A1 (fr) * 2017-07-17 2019-01-24 Keith Roizman Administration topique d'agents therapeutiques comprenant des peptides de penetration cellulaire, destines a etre utilises pour le traitement de la degenerescence maculaire liee a l'age et autres maladies oculaires
WO2019210194A1 (fr) * 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Compositions pegylées à usage oculaire et méthodes associées
MX2022005063A (es) 2019-10-30 2022-08-04 Perfuse Therapeutics Inc Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
IL307997A (en) 2021-04-30 2023-12-01 Perfuse Therapeutics Inc Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
WO2016156639A1 (fr) * 2015-03-27 2016-10-06 Retinset, S.L. Formulation ophtalmique topique d'antagonistes du récepteur de l'endothéline
WO2021158663A1 (fr) * 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions pour le traitement de maladies oculaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HULPKE-WETTE MARTIN ET AL: "BMS-193884 and BMS-207940 Bristol-Myers Squibb BMS-193884 and BMS-207940 Bristol", 1 July 2002 (2002-07-01), pages 1057 - 1061, XP055971907, Retrieved from the Internet <URL:https://www.researchgate.net/publication/11201815> [retrieved on 20221017] *

Also Published As

Publication number Publication date
IL292350A (en) 2022-06-01
US20240189288A1 (en) 2024-06-13
WO2021087399A1 (fr) 2021-05-06
EP4050997A1 (fr) 2022-09-07
CA3158767A1 (fr) 2021-05-06
US20220257568A1 (en) 2022-08-18
CN114786480A (zh) 2022-07-22
MX2022005063A (es) 2022-08-04
CN118203574A (zh) 2024-06-18
CN114786480B (zh) 2024-03-29
US11738007B2 (en) 2023-08-29
EP4094759A1 (fr) 2022-11-30
JP2022554277A (ja) 2022-12-28
AU2020373065A1 (en) 2022-05-26
US20220257505A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
EP4050997A4 (fr) Traitement de maladies oculaires à l&#39;aide d&#39;antagonistes du récepteur de l&#39;endothéline
EP3852735A4 (fr) Agonistes du récepteur farnésoïde x pour le traitement d&#39;une maladie
EP3823568A4 (fr) Traitement chirurgical du glaucome
EP3749374A4 (fr) Récepteurs d&#39;antigènes chimériques pour le traitement des maladies et des troubles neurodégénératifs
IL276383B1 (en) Treatment of ophthalmological diseases
EP3579851A4 (fr) Cellules photoréceptrices pour le traitement de maladies rétiniennes
EP4009948A4 (fr) Utilisation de polypeptides tgf-alpha ou d&#39;anticorps anti-tgf-alpha pour le traitement de maladies et de troubles
EP4065565A4 (fr) Inhibiteurs de la protéine kinase 1 interagissant avec les récepteurs pour le traitement d&#39;une maladie
EP3959213C0 (fr) Inhibiteurs de jak à base de pyrimidine pour le traitement de maladies de la peau
EP4034530A4 (fr) Inhibiteurs de la protéine kinase i interagissant avec des récepteurs pour le traitement d&#39;une maladie
IL289405A (en) Personalized treatment of eye diseases
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP3675889A4 (fr) Angio -3 pour le traitement de maladies angiogéniques rétiniennes
EP4028123A4 (fr) Administration de neuromodulation thérapeutique
EP3644966A4 (fr) Traitement et diagnostic de troubles de surface oculaire
EP3796928A4 (fr) Traitement de la maladie de gaucher
EP3744347A4 (fr) Composition pour une utilisation dans le traitement de maladies cutanées
EP3762092A4 (fr) Stimulation nerveuse non invasive
EP3709982A4 (fr) Composés, compositions et méthodes pour le traitement de troubles oculaires et de maladies cutanées
EP3600324A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3969070A4 (fr) Implant à base de polymère pour thérapie rétinienne et méthodes de fabrication et d&#39;utilisation de celui-ci
IL307794A (en) Treatment of eye diseases using endothelin receptor antagonists
EP3890742A4 (fr) Promédicaments d&#39;agents thérapeutiques contre le cancer et les maladies auto-immunes, et leurs procédés de production et d&#39;utilisation
EP4048201A4 (fr) Prothèses rétiniennes
EP3866779A4 (fr) Traitement de maladies neurologiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A01K0067027000

Ipc: A61K0031402500

A4 Supplementary search report drawn up and despatched

Effective date: 20221031

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101ALI20221025BHEP

Ipc: A61K 9/06 20060101ALI20221025BHEP

Ipc: A61K 9/00 20060101ALI20221025BHEP

Ipc: A61K 47/36 20060101ALI20221025BHEP

Ipc: A61K 47/34 20170101ALI20221025BHEP

Ipc: A61K 47/10 20170101ALI20221025BHEP

Ipc: A61K 45/06 20060101ALI20221025BHEP

Ipc: A61K 31/422 20060101ALI20221025BHEP

Ipc: A61K 31/4025 20060101AFI20221025BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080625

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230510